Status:

COMPLETED

Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes

Lead Sponsor:

The Cleveland Clinic

Conditions:

Bronchopulmonary Dysplasia

Chronic Lung Disease

Eligibility:

All Genders

1-4 years

Brief Summary

Important developmental processes continue until the completion of 40 weeks gestation. Even during fetal life, intrinsic and environmental factors determine the balance between health and the onset an...

Detailed Description

Currently, there is no reliable method to identify infants who will have poor neurodevelopmental and respiratory outcomes. The ability to make such predictions would be beneficial for both making care...

Eligibility Criteria

Inclusion

  • intubated infants in the Neonatal Intensive Care Unit (NICU)

Exclusion

  • unwilling or unable to give or obtain informed consent

Key Trial Info

Start Date :

December 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

August 1 2019

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT03373539

Start Date

December 1 2014

End Date

August 1 2019

Last Update

November 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes | DecenTrialz